Daiichi Sankyo Announces Results of Phase 3 International Joint Trial (RApsody) of Investigational Etanercept Biosimilar

TOKYO, Japan (January 12, 2016) – Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) today announced that they have achieved major objectives in the Phase 3 international joint trial (RApsody) of CHS-0214, an investigational etanercept (genetical recombination) biosimilar*1 in rheumatoid arthritis (RA) under development with the U.S. company, Coherus BioSciences, Inc. (hereinafter, Coherus).

The trial compares the efficacy and safety of CHS-0214 with Enbrel® [generic name: etanercept (genetical recombination); hereinafter, reference product] in RA patients (including Japanese patients) with inadequate response to methotrexate.

The primary endpoint (ACR20*2), evaluating the disease activity of rheumatoid arthritis at 24 weeks after the administration of CHS-0214, met the criteria of equivalence as defined in advance in CHS-0214 and reference product groups, achieving the intended purpose. No significant difference was noted in the reported adverse events between CHS-0214 and reference product groups. Currently, this trial is continued in open-label extension study following the 24-week double-blind phase.

Daiichi Sankyo will continue the development of CHS-0214 based on the strategic alliance with Coherus, concluded for the biosimilar business in Japan in 2012, aiming to enter the biosimilar market to meet diverse medical needs.

Read more on